Zytiga Oral Tablet 250Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

ZYTIGA: Oral tablet (250mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_16889.JPG
Zytiga 250mg Tablet
Janssen Biotech,Inc , formerly Centocor Inc, a Dvision of Orho-McNeil-Janssen Pharmaceuticals, Inc
Pill Identification: AA250 

What is this Medicine?

ABIRATERONE (a bir A ter one) blocks the effect of the male hormone called testosterone. This medicine is used for certain types of prostate cancer.

In-Depth Information

Zytiga 250mg Tablet

NDC: 578940150
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Prostate Cancer

Storage Information
Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
Zytiga 250mg Tablet
Drug Image file DrugItem_16889.JPG
Janssen Biotech,Inc , formerly Centocor Inc, a Dvision of Orho-McNeil-Janssen Pharmaceuticals, Inc
Pill Identification: AA250 
Shape: oval
Color: white

Reported Side Effects for Zytiga 250mg Tablet

Very Rapid Heart Rate Incidence:
<7.2%*
Severity: SEVERE
Onset: EARLY
Fluid Retention Incidence:
<1.9%*
Severity: SEVERE
Onset: DELAYED
Irregular Heart Rate Incidence:
<7.2%*
Severity: SEVERE
Onset: EARLY
Irregular Heart Beat Incidence:
<7.2%*
Severity: SEVERE
Onset: EARLY
High Bilirubin Level Incidence:
0.1%*
Severity: SEVERE
Onset: DELAYED
Inability To Sleep Incidence:
0.2%*
Severity: SEVERE
Onset: EARLY
Hot Flashes Incidence:
0.2-0.3%*
Severity: SEVERE
Onset: EARLY
Increased Urination Incidence:
0.3%*
Severity: SEVERE
Onset: EARLY
High Sodium Levels Incidence:
0.4%*
Severity: SEVERE
Onset: DELAYED
Swelling Incidence:
0.4-1.9%*
Severity: SEVERE
Onset: DELAYED
Constipation Incidence:
0.4%*
Severity: SEVERE
Onset: DELAYED
Chest Pain Incidence:
0.5%*
Severity: SEVERE
Onset: EARLY
Low Steroid Hormones Incidence:
0.5%*
Severity: MODERATE
Onset: DELAYED
Fever Incidence:
0.6%*
Severity: SEVERE
Onset: EARLY
Loose Stools Incidence:
0.6-0.9%*
Severity: SEVERE
Onset: EARLY
Rapid Heart Rate Incidence:
1.1-7.2%*
Severity: SEVERE
Onset: EARLY
Blood In The Urine Incidence:
1.3%*
Severity: SEVERE
Onset: DELAYED
Heart Attack Incidence:
1.3%*
Severity: SEVERE
Onset: DELAYED
High Blood Pressure Incidence:
1.3-3.9%*
Severity: SEVERE
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
1.4-6.1%*
Severity: SEVERE
Onset: DELAYED
Joint Pain Incidence:
2.0-4.2%*
Severity: SEVERE
Onset: DELAYED
Tired Incidence:
2.2%*
Severity: SEVERE
Onset: EARLY
Heart Failure Incidence:
2.3%*
Severity: SEVERE
Onset: DELAYED
Shortness Of Breath Incidence:
2.4%*
Severity: SEVERE
Onset: EARLY
Low Potassium Levels Incidence:
2.8-5.3%*
Severity: SEVERE
Onset: DELAYED
Muscle Pain Incidence:
3.0%*
Severity: SEVERE
Onset: EARLY
Muscle And/Or Bone Pain Incidence:
3.0%*
Severity: SEVERE
Onset: EARLY
Infection Incidence:
5.4-12.7%*
Severity: MILD
Onset: DELAYED
Broken Bones Incidence:
5.9%*
Severity: SEVERE
Onset: DELAYED
Upset Stomach Incidence:
6.1-11.1%*
Severity: MILD
Onset: EARLY
Nighttime Urination Incidence:
6.2%*
Severity: MILD
Onset: EARLY
Increased Blood Sugar Incidence:
6.5%*
Severity: SEVERE
Onset: DELAYED
Low Phosphate Level Incidence:
7.2%*
Severity: SEVERE
Onset: DELAYED
Skin Rash Incidence:
8.1%*
Severity: MILD
Onset: EARLY
Low Lymphocytes Incidence:
8.7%*
Severity: SEVERE
Onset: DELAYED
Cough Incidence:
10.7-17.3%*
Severity: MILD
Onset: DELAYED
Sore Throat Incidence:
10.7%*
Severity: MILD
Onset: DELAYED
High Triglycerides Incidence:
62.1%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

SECOND Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

THIRD Trimester

Class X - Adequate well-controlled or observational studies in animals or pregnant women have demonstrated positive evidence of fetal abnormalities or risks. The use of the product is contraindicated in women who are or may become pregnant.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with ZYTIGA

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5